TEVA-LORAZEPAM TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

LORAZEPAM

Inapatikana kutoka:

TEVA CANADA LIMITED

ATC kanuni:

N05BA06

INN (Jina la Kimataifa):

LORAZEPAM

Kipimo:

0.5MG

Dawa fomu:

TABLET

Tungo:

LORAZEPAM 0.5MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100/500/1000

Dawa ya aina:

Targeted (CDSA IV)

Eneo la matibabu:

BENZODIAZEPINES

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0110731003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2013-12-06

Tabia za bidhaa

TEVA-LORAZEPAM Page 1 of 33
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TEVA-LORAZEPAM
Lorazepam Tablets
Tablets, 0.5 mg, 1 mg, 2 mg, Oral
Teva Standard
Anxiolytic-Sedative
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Date of Initial Authorization:
March 05, 1985
Date of Revision:
March 24, 2023
Submission Control No.: 271985
TEVA-LORAZEPAM Page 2 of 33
RECENT MAJOR LABEL CHANGES
1 Indications
03/2023
1 Indications, 1.2 Geriatrics
12/2021
3 Serious Warnings and Precautions Box
12/2021
4 Dosage and Administration, 4.1 Dosing Considerations
12/2021
4 Dosage and Administration, 4.2 Recommended Dose and Dosage
Adjustment
03/2023
7 Warnings and Precautions
03/2023
7 Warnings and Precautions, 7.1.4 Geriatrics
12/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES……………………………………………………………………………………………2
TABLE OF
CONTENTS……………………………………………………………………………………………………………..2
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................
4
1 INDICATIONS
...........................................................................................................................
4
1.1
Pediatrics………………………………………………………………………………………………………………………….4
1.2
Geriatrics…..……………………………………………………………………………………………………………………..4
2 CONTRAINDICATIONS
.............................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
4
4 DOSAGE AND
ADMINISTRATION…………………………………�